Ashkan Shoamanesh: FDA Grants Asundexian A Priority Review for Secondary Stroke Prevention
Ashkan Shoamanesh, Associate Professor of Medicine (Neurology), Marta and Owen Boris Chair in Stroke Research and Care at McMaster University, shared on LinkedIn:
”Excellent news for patients with ischemic stroke and high-risk TIA: the U.S. FDA has granted Priority Review to asundexian for secondary stroke prevention based on the results of the OCEANIC-STROKE trial.
This marks an important step toward the potential rapid availability of a novel treatment strategy aimed at reducing recurrent ischemic events without increasing major bleeding risk – a long-standing unmet need in stroke prevention.
Very hopeful that other global regulatory agencies will follow suit so that patients worldwide may benefit from timely access to this therapy.”
Stay updated on all scientific advances with Hemostasis Today.
-
Jul 2, 2026, 19:40Minoo Ahmadinejad: Improving the Recognition of Women and Girls With Hemophilia
-
Jul 2, 2026, 19:26Dhinesh Selvaraju: FDA Expands Access to HYMPAVZI in Hemophilia
-
Jul 2, 2026, 19:13Syed Fahad Hussain: Not Every Low Platelet Count Tells the Same Story
-
Jul 2, 2026, 18:59Indu Thakur: Supporting Blood Donation Through Public Awareness in MSBT
-
Jul 2, 2026, 18:47Vee Townsend: IMHUE Highlights 9 Myths and Facts About Hemophilia B
-
Jul 2, 2026, 17:17Nico Gagelmann: Launching Myths and Facts on Hematology and Cell Therapy
-
Jul 2, 2026, 17:05Haroun Gajraj: Understanding the Technology Behind Spider Vein Treatment
-
Jul 2, 2026, 16:44Ney Carter Borges: Is It Time to Personalize Antiplatelet Therapy?
-
Jul 2, 2026, 16:22Introducing a New Resource for the ITP Community – ITP Support Association